R&D channel feed – Endpoints News

R&D channel feed

Woeful Axovant starts axing staff, but departing CEO David Hung gets a $2.6M exit package/bonus

8 years ago

CureVac to develop mRNA-based flu, malaria vaccines with new Gates Foundation grants

8 years ago

Biogen shares tumble after key exec notes a changeup to pivotal aducanumab study due to 'variability'

8 years ago

Stock slumps for Tel Aviv's Galmed following PhIIa NAFLD flop

8 years ago

Merck just dashed the last remaining hopes for its industry-leading BACE drug for Alzheimer's

8 years ago

Tetraphase’s second PhIII for its lead antibiotic fails in a repeat setback for UTIs

8 years ago

$100B in NIH-funded research played an important role in all 210 new drugs approved over 7 years — study

8 years ago

Eli Lilly touts PhIII success for Taltz as rival Novartis stays well out front in crowded immunology race

8 years ago

New year, new tax rates. How did the world’s biggest drugmakers fare?

8 years ago

What's the trouble with pain? Analysis shows scarce investments, high failure rate for new drugs

8 years ago

Roche posts positive PhII results for bispecific antibody eye drug, joining Novartis in rivalry with Eylea

8 years ago

Sarepta halts its golodirsen Duchenne MD study in UK after patient experiences adverse event

8 years ago

Seattle Genetics seeds a new immuno-oncology collaboration with the protein explorers at Pieris

8 years ago

Scientists toss another Alzheimer’s program into the scrap heap as PhII fails

8 years ago

Madrigal touts a mid-stage success in HeFH, cutting bad cholesterol in a competitive field

8 years ago

No more Mr Nice Guy: GlaxoSmithKline is coming out of its corner swinging

8 years ago

Sanofi sounds taps on a half dozen drug programs in latest pipeline cleanup

8 years ago

Biogen scuttles a Tysabri program after the drug fails stroke test, thinning the pipeline

8 years ago

Array MEK/BRAF combo beats out Roche rival in PhIII melanoma OS showdown

8 years ago

Eyeing a blockbuster migraine market, Allergan takes an inside track on acute cases with positive PhIII

8 years ago

Looking to grow blockbuster Pomalyst franchise, Celgene declares a win for multiple myeloma triplet in pivotal PhIII

8 years ago

Roche hails another PhIII win on Tecentriq combo, reports promising kidney cancer data

8 years ago

Pfizer vs J&J: Researchers are duking it out for the championship title in nonmetastatic prostate cancer

8 years ago

Bristol-Myers offers some eagerly awaited Checkmate-227 results, but they're not changing medical practice -- yet

8 years ago

First page Previous page 282 283 284285286 287 288 Next page Last page